{"title":"全球生物仿制药开发:15年积极监管经验后有整合机会吗?","authors":"Z. Holló","doi":"10.33892/aph.2021.91.138-139","DOIUrl":null,"url":null,"abstract":"Biological drugs are highly innovative pharmaceuticals derived from living cells or organisms for the treatment of high-burden diseases such as cancer, autoimmune/chronic inflammatory, cardiovascular, metabolic and central nervous system diseases. Biosimilar medicines have been developed after the patent expiry of originator biological drugs in order to facilitate access to these effective drugs, at a reduced cost.","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"588 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Global Biosimilar Drug Development: Any Chance for Consolidation after 15 Years of Positive Regulatory Experience?\",\"authors\":\"Z. Holló\",\"doi\":\"10.33892/aph.2021.91.138-139\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Biological drugs are highly innovative pharmaceuticals derived from living cells or organisms for the treatment of high-burden diseases such as cancer, autoimmune/chronic inflammatory, cardiovascular, metabolic and central nervous system diseases. Biosimilar medicines have been developed after the patent expiry of originator biological drugs in order to facilitate access to these effective drugs, at a reduced cost.\",\"PeriodicalId\":6941,\"journal\":{\"name\":\"Acta pharmaceutica Hungarica\",\"volume\":\"588 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta pharmaceutica Hungarica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33892/aph.2021.91.138-139\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta pharmaceutica Hungarica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33892/aph.2021.91.138-139","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Global Biosimilar Drug Development: Any Chance for Consolidation after 15 Years of Positive Regulatory Experience?
Biological drugs are highly innovative pharmaceuticals derived from living cells or organisms for the treatment of high-burden diseases such as cancer, autoimmune/chronic inflammatory, cardiovascular, metabolic and central nervous system diseases. Biosimilar medicines have been developed after the patent expiry of originator biological drugs in order to facilitate access to these effective drugs, at a reduced cost.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
